Enhancing the development of immune cells from blood stem cells using linker histones
Official title: Driving lymphoid potential in multipotent hematopoietic progenitors by linker histones
Funded at Yale University · NIH-11172039 · Data updated 2026-11-12
This study is looking at how certain proteins called linker histones can help blood stem cells turn into important immune cells, which could lead to new treatments for diseases like cancer and inflammation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $560,828 |
| NIH project number | 1R56HL173442-01 |
| Project ID | NIH-11172039 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions related to impaired immune function or blood disorders, such as certain types of cancer or myeloproliferative diseases.
✕Less likely to help
Patients with stable immune function and no underlying hematological disorders may not benefit from this research.
What this research studies
This research investigates how linker histones can influence the differentiation of multipotent hematopoietic stem and progenitor cells (HSPCs) into lymphoid cells, which are crucial for a healthy immune system. By using a mouse model with a specific genetic modification, the researchers aim to understand the molecular pathways that promote lymphoid lineage over myeloid lineage in these cells. The study will explore the effects of different linker histone isoforms on the potential of HSPCs to develop into various types of immune cells, potentially leading to new therapeutic strategies for conditions like cancer and inflammation.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for cancers and immune disorders by enhancing the body's ability to produce healthy lymphoid cells.
How similar studies have gone: While the specific approach of using linker histones to drive lymphoid potential is novel, similar research has shown promise in manipulating stem cell differentiation for therapeutic purposes.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Guo, Shangqin — Yale University
- Study coordinator: Guo, Shangqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.